Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol + lubiprostone is a combination therapy used primarily for bowel preparation before colonoscopy and for the management of constipation, particularly in patients with chronic idiopathic constipation or those who are difficult to prep, such as individuals with diabetes. Polyethylene glycol (PEG) acts as an osmotic laxative by retaining water in the colon, thereby softening stools and promoting bowel movements. Lubiprostone is a prostaglandin E1 derivative that activates chloride channel protein 2 (ClC-2) on gastrointestinal epithelial cells, increasing chloride-rich fluid secretion into the intestinal lumen, which further softens stool and enhances motility. The combination has been studied to determine if it improves bowel cleansing efficacy compared to PEG alone; some studies suggest modest improvement in certain populations (e.g., diabetics), while others show no significant additional benefit over PEG alone[1][2][4]. Both agents are approved individually for constipation-related indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol + lubiprostone.